ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Halozyme Therapeutics Inc

Halozyme Therapeutics Inc (0J2O)

18.26
0.00
(0.00%)
Cerrado 05 Enero 10:30AM

Su centro para precios en tiempo real, ideas y debates en vivo

Estadísticas y detalles clave

Último Precio
18.26
Postura de Compra
0.00
Postura de Venta
0.00
Volume Operado de la Acción
1,498
0.00 Rango del Día 0.00
18.26 Rango de 52 semanas 18.26
Capitalización de Mercado [m]
Precio Anterior
18.26
Precio de Apertura
-
Última hora de negociación
Volumen financiero
-
Precio Promedio Ponderado
-
Volumen promedio (3 m)
1,690
Acciones en circulación
132,098,000
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
22.39
Beneficio por acción (BPA)
2.13
turnover
829.25M
Beneficio neto
281.59M

Acerca de Halozyme Therapeutics Inc

Sector
Biological Pds,ex Diagnstics
Industria
Biological Pds,ex Diagnstics
Sitio web
Sede
Wilmington, Delaware, USA
Fundado
-
Halozyme Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the London Stock Exchange with ticker 0J2O. The last closing price for Halozyme Therapeutics was US$18.26. Over the last year, Halozyme Therapeutics shares have traded in a share price range of US$ 18.26 to US$ 18.26.

Halozyme Therapeutics currently has 132,098,000 shares in issue. The market capitalisation of Halozyme Therapeutics is US$2.41 billion. Halozyme Therapeutics has a price to earnings ratio (PE ratio) of 22.39.

0J2O Últimas noticias

No news to show yet.
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10018.2618.2618.2629818.26DE
40018.2618.2618.26121818.26DE
120018.2618.2618.26169018.26DE
260018.2618.2618.26126418.26DE
520018.2618.2618.26117818.26DE
1560018.2618.2618.2660618.26DE
2600018.2618.2618.2649418.26DE

0J2O - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Halozyme Therapeutics?
El precio actual de las acciones de Halozyme Therapeutics es US$ 18.26
¿Cuántas acciones de Halozyme Therapeutics están en circulación?
Halozyme Therapeutics tiene 132,098,000 acciones en circulación
¿Cuál es la capitalización de mercado de Halozyme Therapeutics?
La capitalización de mercado de Halozyme Therapeutics es USD 2.41B
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Halozyme Therapeutics?
Halozyme Therapeutics ha negociado en un rango de US$ 18.26 a US$ 18.26 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Halozyme Therapeutics?
El ratio precio/beneficio de Halozyme Therapeutics es 22.39
¿Cuál es el ratio de efectivo a ventas de Halozyme Therapeutics?
El ratio de efectivo a ventas de Halozyme Therapeutics es 7.6
¿Cuál es la moneda de reporte de Halozyme Therapeutics?
Halozyme Therapeutics presenta sus resultados financieros en USD
¿Cuál es el último ingresos anual de Halozyme Therapeutics?
El último ingresos anual de Halozyme Therapeutics es USD 829.25M
¿Cuál es el último beneficio anual de Halozyme Therapeutics?
El último beneficio anual de Halozyme Therapeutics es USD 281.59M
¿Cuál es la dirección registrada de Halozyme Therapeutics?
La dirección registrada de Halozyme Therapeutics es 1209 ORANGE STREET, NEW CASTLE, WILMINGTON, DELAWARE, 19801
¿Cuál es la dirección del sitio web de Halozyme Therapeutics?
La dirección del sitio web de Halozyme Therapeutics es www.halozyme.com
¿En qué sector industrial opera Halozyme Therapeutics?
Halozyme Therapeutics opera en el sector BIOLOGICAL PDS,EX DIAGNSTICS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
TCFTheracryf Plc
0.725p
(38.10%)
7.56M
NMTNeometals Ltd
3.50p
(27.27%)
346.81k
SCHOScholium Group Plc
44.00p
(25.71%)
30.65k
FABFusion Antibodies Plc
10.15p
(24.54%)
3.34M
PYXPyx Resources Limited
3.49p
(22.24%)
8.43k
TM1Technology Minerals Plc
0.125p
(-24.24%)
37.21M
QUIZQuiz Plc
0.70p
(-18.60%)
3.67M
SYMESupply@me Capital Plc
0.003p
(-17.81%)
168.35M
OBDOxford Biodynamics Plc
1.20p
(-14.29%)
827.83k
ZENZenith Energy Ltd.
5.25p
(-13.93%)
5.39M
TRPTower Resources Plc
0.0395p
(5.33%)
539.51M
CPXCap-xx Limited
0.1825p
(1.39%)
494M
NTVONativo Resources Plc
0.0019p
(0.00%)
320.16M
DGIDg Innovate Plc
0.0225p
(-13.46%)
208.21M
ENETEthernity Networks Ltd
0.1125p
(2.27%)
207.56M
sand sand 7 minutos hace
Thank you Ducci for all your sharing and insights extremely helpful. I'm slowly diligently getting there rewiring the brain and focusing on what shows the moves. Much continued success this week. Thank you again.
SPY
mining101 mining101 8 minutos hace
Moving hard soon 
EFSH
mining101 mining101 9 minutos hace
Superb
MEGL
benz280c benz280c 16 minutos hace
Speak louder and maybe you will convince somebody that this is how you really feel. No need to be insecure around your fellow investors.
GDVM
rx7171 rx7171 23 minutos hace
In addition MABs are approved for only a limited portion of the AD population, whereas Blarcamasine appears to be effective in 70-80% of the ITT population with its strongest efficacy in the 70% with wild type Sigma-1.
AVXL
TheHound TheHound 24 minutos hace
Learn how to use the bull market support band with that chart and you’ll have a powerful tool under your belt!
XRPUSD
Investor2014 Investor2014 27 minutos hace
When I say that the totality of information is what Anavex rely on it does take into account the pretty ineffective SOC, associated risks and inconveniences for patients.

Still any drug regulatory process must and should look carefully at the data to ensure that neither type one or tw
AVXL
nowwhat2 nowwhat2 32 minutos hace
Just learnt of the Total 3 today.......Appears to be a good thing to have learnt of.

3 month
https://investorshub.advfn.com/uimage/uploads/2025/1/5/siwcoTOTAL_3_!_4_3M_JUNCT_DAY_1.jpg



Because how the overall mkt resolves itself is gonna'r have con
BTCUSD
rx7171 rx7171 33 minutos hace
Yes that spike to $23 in June of 2021 was driven entirely by the excellent Phase II data for PDD.

Yet now after completing the AD 2b/3 trial and having an EMA MAA accepted for evaluation the share price is barely half that number!

I understand the company being very ca
PDD
sunspotter sunspotter 38 minutos hace
Black Cat Moan was one of my favorites back in the day:

https://youtu.be/cxN-frB1UbI?si=Ph6XMC3omR0rRlmR

Edit: auto correct changed Moan to Moana. The cultural prevalence of Disney.
Investor2014 Investor2014 40 minutos hace
The ex-biotech executive is back in the Rett trap posting mode - hope it goes better with the biased approach this time.

Listing all the site PI’s is not world class peer review WGT confirmation.
AVXL
nowwhat2 nowwhat2 41 minutos hace
Just learnt of the Total 3 today.......Appears to be a good thing to have learnt of.

3 month
https://investorshub.advfn.com/uimage/uploads/2025/1/5/siwcoTOTAL_3_!_4_3M_JUNCT_DAY_1.jpg



Because how the overall mkt resolves itself is gonna'r have con
sunspotter sunspotter 43 minutos hace
I rather think you missed the point. It’s not that higher doses of GALT’s drug are toxic, it’s that they are ineffective.

Given the purported mechanism, that almost certainly means lower doses are too, and that the implication that the lower dose worked is merely an artefact.
GALT
nowwhat2 nowwhat2 46 minutos hace
Just learnt of the Total 3 today.......Appears to be a good thing to have learnt of.

3 month
https://investorshub.advfn.com/uimage/uploads/2025/1/5/siwcoTOTAL_3_!_4_3M_JUNCT_DAY_1.jpg



Because how the overall mkt resolves itself is gonna'r have con
XRPUSD
CrossFireTrader CrossFireTrader 49 minutos hace
I try to avoid Krispy Kreme's af all costs. Thanks for your insight...
GDVM
skitahoe skitahoe 49 minutos hace
Dstock, you may be very right about the data from compassionate use being included, but if it is, I would think that the protocols used on every one of those patients would need to be included as none are specifically on the trial protocol. It's essentially anecdotal evidence, but it could all add
NWBO
Pickme2 Pickme2 50 minutos hace
Stop wasting our time with your ongoing Manipulated nonsense.... Just read the S-1 
Filed with the sec.... 


ATMH
georgejjl georgejjl 51 minutos hace
The MABs are no where near being the standard of care for treating Alzheimer’s patients.
AVXL
benz280c benz280c 53 minutos hace
Phone died when responding to that. In summary, I think the 24/7 is multi-pronged. It is necessary for the kind of business that Veemost is and will be, which aligns it and will help it qualify for Gold. I do not recall it expressly said that Gold was reached and turned down. Not saying that didn't
GDVM
Sheepdog Sheepdog 1 hora hace
Really? So you think the SEC is going to start arresting OTC Scammers and Pump/Dumpers? I hope so...about time.
GCAN
Hummingbird2 Hummingbird2 1 hora hace
$GTII ~ Just listen in the first 5 mins about $GTII 🛫 after March? https://www.youtube.com/watch?v=Ag2f2rDlq5g
GTII
Jane1999 Jane1999 1 hora hace
Here the CEO : https://www.wsj.com/market-data/quotes/CA/XCNQ/TWOH/company-people/executive-profile/149699
TWOH
Curious Bystander Curious Bystander 1 hora hace
The Expert Market was set up by the SEC for several very specific reasons. But you could generally say that a security lands in that market when a company is either UNABLE or UNWILLING to file certain SEC-required forms.

UNABLE or UNWILLING. Hmmmm…..I wonder which category Quantum
FLCX

Su Consulta Reciente

Delayed Upgrade Clock